New hope for tough esophageal cancer: SYS6010 trial launches
NCT ID NCT07417735
First seen Feb 22, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study tests a new drug called SYS6010 against standard chemotherapy for people with advanced or returning esophageal cancer that has not responded to at least one prior treatment. About 436 adults will be randomly assigned to receive either SYS6010 or a standard chemo drug. The goal is to see if SYS6010 can slow cancer growth or improve survival better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC/RECURRENT ESCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.